Log in

Cutera Stock Forecast, Price & News

-0.42 (-2.29 %)
(As of 09/24/2020 12:00 AM ET)
Today's Range
Now: $17.89
50-Day Range
MA: $16.71
52-Week Range
Now: $17.89
Volume176,443 shs
Average Volume250,462 shs
Market Capitalization$314.76 million
P/E RatioN/A
Dividend YieldN/A
Cutera, Inc., a medical device company, designs, develops, manufactures, markets, and services laser and other energy based aesthetics systems worldwide. The company offers enlighten platform, a laser system that is used for tattoo removal, as well as for the treatment of benign pigmented lesions; excel HR platform, a hair removal solution for various skin types; and truSculpt, a high-powered radio frequency platform designed for deep tissue heating. It also provides excel V, a vascular and benign pigmented lesion treatment platform; xeo platform, a multi-application platform on which a customer purchases hand piece applications for the removal of unwanted hair, treatment of vascular lesions, and skin revitalization by treating discoloration, fine lines, and laxity; Juliet, a laser system for vaginal health; and Secret RF, a fractional radio frequency microneedling device for skin revitalization. In addition, the company offers GenesisPlus, CoolGlide, myQ, enlighten SR, and truSculpt iD products. Further, it provides pulsed light hand pieces for the treatment of discoloration, hair removal, and vascular treatments; Pearl and Pearl Fractional hand pieces; and post-warranty services through extended service contracts or direct billing, as well as offers Titan hand piece refills and marketing brochures through the Internet. The company markets and sells its products through direct sales force to plastic surgeons, dermatologists, gynecologists, family practitioners, primary care physicians, physicians performing aesthetic treatments in non-medical offices, and other qualified practitioners, as well as for physicians offering aesthetic treatments in non-medical offices. Cutera, Inc. was founded in 1998 and is headquartered in Brisbane, California.
Read More
Cutera logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.12 out of 5 stars

Industry, Sector and Symbol

Industry Electromedical equipment
Current SymbolNASDAQ:CUTR



Sales & Book Value

Annual Sales$181.71 million
Book Value$3.23 per share


Net Income$-12,350,000.00


Market Cap$314.76 million
Next Earnings Date11/5/2020 (Estimated)
-0.42 (-2.29 %)
(As of 09/24/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CUTR News and Ratings via Email

Sign-up to receive the latest news and ratings for CUTR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Cutera (NASDAQ:CUTR) Frequently Asked Questions

How has Cutera's stock price been impacted by Coronavirus (COVID-19)?

Cutera's stock was trading at $18.11 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CUTR stock has decreased by 1.2% and is now trading at $17.89.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Cutera?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cutera in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Cutera

When is Cutera's next earnings date?

Cutera is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Cutera

How were Cutera's earnings last quarter?

Cutera, Inc. (NASDAQ:CUTR) issued its quarterly earnings results on Thursday, August, 6th. The medical device company reported ($0.67) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.94) by $0.27. The medical device company earned $26.37 million during the quarter, compared to analysts' expectations of $20.20 million. Cutera had a negative net margin of 18.22% and a negative return on equity of 64.84%.
View Cutera's earnings history

What price target have analysts set for CUTR?

4 equities research analysts have issued 12 month price objectives for Cutera's shares. Their forecasts range from $18.00 to $26.00. On average, they expect Cutera's share price to reach $22.67 in the next year. This suggests a possible upside of 26.7% from the stock's current price.
View analysts' price targets for Cutera

Are investors shorting Cutera?

Cutera saw a increase in short interest in August. As of August 31st, there was short interest totaling 584,800 shares, an increase of 30.0% from the August 15th total of 449,800 shares. Based on an average daily trading volume, of 236,300 shares, the days-to-cover ratio is currently 2.5 days.
View Cutera's Short Interest

Who are some of Cutera's key competitors?

What other stocks do shareholders of Cutera own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cutera investors own include NVIDIA (NVDA), QUALCOMM (QCOM), AbbVie (ABBV), Micron Technology (MU), Gilead Sciences (GILD), Alibaba Group (BABA), Docusign (DOCU), Pfizer (PFE), Square (SQ) and Twilio (TWLO).

Who are Cutera's key executives?

Cutera's management team includes the following people:
  • Ms. Sandra A. Gardiner, Exec. VP & CFO (Age 53)
  • Mr. Larry E. Laber, Exec. VP of Sales - North America (Age 48)
  • Mr. Ronald J. Santilli, Exec. Officer (Age 59)
  • Mr. Jason Richey, Interim CEO & Chief Operating Officer
  • Dr. Michael Karavitis, Exec. VP & Chief Technology Officer

What is Cutera's stock symbol?

Cutera trades on the NASDAQ under the ticker symbol "CUTR."

Who are Cutera's major shareholders?

Cutera's stock is owned by many different retail and institutional investors. Top institutional investors include Victory Capital Management Inc. (8.75%), Gamco Investors INC. ET AL (6.48%), Gabelli Funds LLC (3.50%), Assenagon Asset Management S.A. (2.08%), Teton Advisors Inc. (1.95%) and Federated Hermes Inc. (1.27%). Company insiders that own Cutera stock include David H Mowry, J Daniel Plants and Katherine S Zanotti.
View institutional ownership trends for Cutera

Which major investors are selling Cutera stock?

CUTR stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Jacobs Levy Equity Management Inc., Teton Advisors Inc., Gabelli Funds LLC, Mackay Shields LLC, AQR Capital Management LLC, Essex Investment Management Co. LLC, and Bank of America Corp DE.
View insider buying and selling activity for Cutera

Which major investors are buying Cutera stock?

CUTR stock was bought by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Assenagon Asset Management S.A., Cadence Capital Management LLC, WINTON GROUP Ltd, Engineers Gate Manager LP, Russell Investments Group Ltd., Federated Hermes Inc., and Aigen Investment Management LP. Company insiders that have bought Cutera stock in the last two years include David H Mowry, J Daniel Plants, and Katherine S Zanotti.
View insider buying and selling activity for Cutera

How do I buy shares of Cutera?

Shares of CUTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cutera's stock price today?

One share of CUTR stock can currently be purchased for approximately $17.89.

How big of a company is Cutera?

Cutera has a market capitalization of $314.76 million and generates $181.71 million in revenue each year. The medical device company earns $-12,350,000.00 in net income (profit) each year or ($0.88) on an earnings per share basis. Cutera employs 402 workers across the globe.

What is Cutera's official website?

The official website for Cutera is www.cutera.com.

How can I contact Cutera?

Cutera's mailing address is 3240 BAYSHORE BOULEVARD, BRISBANE CA, 94005. The medical device company can be reached via phone at 415-657-5500 or via email at [email protected]

This page was last updated on 9/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.